Core - Experimental Therapeutics Core (ETx)

Overview of Services

The Experimental Therapeutics (ETx) Core is a preclinical resource to Dana-Farber Cancer Institute (DFCI) researchers and collaborators for conducting in vivo pharmacological studies. Studies will be run at a 14,000-square-foot preclinical facility shared with the Lurie Family Imaging Center (LFIC) that features bioluminescent imaging using the IVIS Spectrum system.

 

Our mission is to help DFCI investigators by providing high quality in vivo pharmacology studies that enable DFCI investigators’ translational research and chemistry and drug discovery/development efforts. These include studies that determine efficacy of new therapies and new combinations, advance preclinical studies to initiate clinical trials, and target identification and validation.

 

The Experimental Therapeutics Core will provide expertise for in vivo pharmacology studies, including drug tolerability and efficacy studies; pharmacodynamic and mechanism-of-action studies, and tumor model development. Our capabilities include both subcutaneous and orthotopic tumor implantations and animal dosing by all common routes of administration, e.g. intraperitoneal, intravenous, oral and subcutaneous, and in combination. Comprehensive tumor and tissue harvesting is available for every study. Fresh samples can be sent to investigators or preserved by formalin fixation and/or flash freezing.

Information for Users External to DFCI

Purchase Orders are to be made out to:

Dana Farber Cancer Institute

General Accounting, BP-430

450 Brookline Avenue

Boston, MA 02215-5450

 

Note to Partners, Harvard, Boston Children’s and Tufts researchers:

  • Partners Health Care (includes MGH, BWH, McLean, Spaulding, etc): choose vendor 0000008813
  • Harvard (includes HMS,Dental, Wyss, HSPH, etc.): choose vendor site: 01_PRIMARY
  • Tufts University: choose Supplier 0000000655
  • Boston Children’s Hospital: choose vendor 0000001886
  • Beth Israel: use Supplier 54532

 

 If you are using a PO from an institution other than one under which you signed in, you must stop and contact the DFCI iLab staff at sc_billing@dfci.harvard.edu


 

Leadership

Prafulla Gokhale, Ph.D., Head of the Experimental Therapeutics Core

Paul T. Kirschmeier, Ph.D., Head of Cancer Therapeutics at the Belfer Institute

Administrative Contacts

Debbie Taylor-Nicoleau, Core Administration, Experimental Therapeutics Core

 

Location and hours of operation

Hours Location

8:00 AM - 4:00 PM  

27 Dry Dock Ave, Boston, MA 02210

 

Links and Resources

  1. To initiate a project go to the Request Services Tab and click Initate a project.
  2. ARF: http://dfciarf.partners.org/main.aspx

Contacts

Name Role Phone Email Location
Debbie Taylor-Nicoleau
Research Administration
 
(617) 582-8969
 
Debbie_Taylor-Nicoleau@dfci.harvard.edu
 
DD-109
 
Dr. Praful Gokhale
Head of the Experimental Therapeutics Core
 
(617) 632-6919
 
Prafulla_Gokhale@dfci.harvard.edu
 

 
Dr. Paul T. Kirschmeier
Head of Cancer Therapeutics at the Belfer Institute
 
(617) 582-9616
 
Pault_Kirschmeier@dfci.harvard.edu
 

 

Services

Name Description